Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.79 |
| ▸ | DHODH | Q02127 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | EPRS1 | P07814 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | PPARG | P37231 | 3/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12237494 | 0.97 | RXFP1 (0.75) | RXFP1DHODHKDM4ELMNASMN1; SMN2 | |
| SCHEMBL117430 | 0.92 | EPRS1 (0.79) | RXFP1DHODHKDM4ELMNAHSD17B10 | |
| SCHEMBL12237496 | 0.92 | RXFP1 (0.67) | RXFP1DHODHKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1898124 | 0.90 | KDM4E (0.72) | RXFP1DHODHKDM4ELMNASMN1; SMN2 | |
| SCHEMBL7814193 | 0.88 | GAA (0.71) | RXFP1DHODHKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL5530291 | 0.88 | EPRS1 (0.85) | RXFP1DHODHKDM4ELMNAHSD17B10 | |
| SCHEMBL7821284 | 0.88 | KMT2A (0.81) | RXFP1DHODHKDM4ELMNASMN1; SMN2 | |
| SCHEMBL5838639 | 0.87 | DHODH (0.74) | RXFP1DHODHKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL18320549 | 0.87 | DHODH (0.76) | RXFP1DHODHKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL12237416 | 0.87 | RXFP1 (0.65) | RXFP1DHODHKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169640-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3943159-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | Kabushiki Kaisha Yakult Honsha (JP) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020196327-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | 株式会社ヤクルト本社 | 2020-10-01 | — | — | WO | disclosed |
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-8466290-B2 | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2011-07-14 | — | — | US | disclosed |
| CN-102099352-A | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INC ASS | 2011-06-15 | — | — | CN | disclosed |
| EP-2325181-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | Pharma Ip General Incorporated Association (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169640-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | BCKDK, CBR3, NQO2 | RXFP1 2121/4885DHODH 45/4885KDM4E 363/4885 |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | STAT3, STAT4, STAT5B | RXFP1 97/4885DHODH 3326/4885KDM4E 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.